Department of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA.
University of Michigan Congenital Heart Center, Ann Arbor, Michigan, USA.
Pediatr Transplant. 2022 Mar;26(2):e14196. doi: 10.1111/petr.14196. Epub 2021 Nov 24.
Although mortality has decreased considerably in pediatric heart transplantation, waitlist and post-transplant death rates remain notable. End-of-life focused research in this population, however, is very limited. This Pediatric Heart Transplant Society study aimed to describe the circumstances surrounding death of pediatric heart transplant patients.
A retrospective analysis of the multi-institutional, international, Pediatric Heart Transplant Society registry was conducted. Descriptive statistics and univariate analyses were performed to 1) describe end-of-life in pediatric pre- and post-heart transplant patients and 2) examine associations between location of death and technological interventions at end-of-life with demographic and disease factors.
Of 9217 patients (0-18 years) enrolled in the registry between 1993 and 2018, 2804 (30%) deaths occurred; 1310 while awaiting heart transplant and 1494 post-heart transplant. The majority of waitlist deaths (89%) occurred in the hospital, primarily in ICU (74%) with most receiving mechanical ventilation (77%). Fewer post-transplant deaths occurred in the hospital (22%). Out-of-hospital death was associated with older patient age (p < .01).
ICU deaths with high use of technological interventions at end-of-life were common, particularly in patients awaiting heart transplant. In this high mortality population, findings raise challenging considerations for clinicians, families, and policy makers on how to balance quality of life amidst high risk for hospital-based death.
尽管儿科心脏移植患者的死亡率已大幅下降,但候补名单和移植后死亡率仍然显著。然而,该人群的临终关怀研究非常有限。这项儿科心脏移植协会的研究旨在描述儿科心脏移植患者死亡的情况。
对多机构、国际儿科心脏移植协会注册中心进行了回顾性分析。采用描述性统计和单变量分析,1)描述儿科心脏移植患者在移植前和移植后的临终情况,2)检查临终时死亡地点和技术干预与人口统计学和疾病因素之间的关系。
在 1993 年至 2018 年间注册的 9217 名患者(0-18 岁)中,有 2804 名(30%)死亡;1310 人在等待心脏移植,1494 人在心脏移植后。候补名单上死亡的大多数(89%)发生在医院,主要是在 ICU(74%),其中大多数人接受机械通气(77%)。在医院的移植后死亡较少(22%)。院外死亡与患者年龄较大有关(p<0.01)。
在等待心脏移植的患者中,临终时 ICU 死亡与高频率使用技术干预措施很常见。在这个高死亡率的人群中,这些发现给临床医生、家属和政策制定者带来了严峻的挑战,需要考虑如何在高医院死亡风险的情况下平衡生活质量。